Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
Open Access
- 24 November 2017
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 59 (4) , 646-651
Abstract
Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been tested in several clinical trials, often with promising results, but have never proven curative. Methods: We have previously presented simulations of clinically relevant amounts of intraperitoneal 90Y-mAbs for treatment of minimal disease and shown that such treatments are unlikely to eradicate microtumors. Our previous model simulated the kinetics of intraperitoneally infused radiolabeled mAbs in humans and showed the benefit of instead using α-emitters such as 211At. In the current work, we introduce penetration of mAbs into microtumors with radii of up to 400 μm. Calculations were performed using dynamic simulation software. To determine the radiation dose distribution in nonvascularized microtumors of various sizes after intraperitoneal 211At-radioimmunotherapy, we used an in-house–developed Monte Carlo program for microdosimetry. Our aim was to find methods that optimize the therapy for as wide a tumor size range as possible. Results: Our results show that high-specific-activity radiolabeled mAbs that are bound to a tumor surface will penetrate slowly compared with the half-lives of 211At and shorter-lived radionuclides. The inner-core cells of tumors with radii exceeding 100 μm may therefore not be sufficiently irradiated. For lower specific activities, the penetration rate and dose distribution will be more favorable for such tumors, but the dose to smaller microtumors and single cells will be low. Conclusion: Our calculations show that the addition of a boost with unlabeled mAb 1–5 h after therapy results in sufficient absorbed doses both to single cells and throughout microtumors up to approximately 300 μm in radius. This finding should also hold for other high-affinity mAbs and short-lived α-emitters.Keywords
This publication has 12 references indexed in Scilit:
- Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian CancerCancer Research, 2016
- Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-TrastuzumabJournal of Nuclear Medicine, 2014
- The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and BeyondFrontiers in Oncology, 2014
- A mechanistic compartmental model for total antibody uptake in tumorsJournal of Theoretical Biology, 2012
- Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I StudyJournal of Nuclear Medicine, 2009
- Direct Procedure for the Production of211At-Labeled Antibodies with an ε-Lysyl-3-(Trimethylstannyl)Benzamide ImmunoconjugateJournal of Nuclear Medicine, 2008
- Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor SpheroidsCancer Research, 2008
- Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete RemissionJournal of Clinical Oncology, 2006
- Microdosimetry of astatine-211 single-cell irradiation: Role of daughter polonium-211 diffusionMedical Physics, 2004